Tag: well

Watsonville, CA, June 26, 2026 (GLOBE NEWSWIRE) -- Nordic Naturals, the #1 selling fish oil brand in the U.S.‡, today announced that its award-winning Ultimate Omega® is a featured ingredient in Erewhon's newly launched, limited-edition “Chimba de Smoothie by J Balvin.”

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- WeRide Inc. (“WeRide” or the “Company”) (NASDAQ: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced that each of the proposed resolutions submitted for shareholders’ approval (the “Proposed Resolutions”) as set forth in the notice of the annual general meeting dated May 8, 2026, Beijing time (the “AGM Notice”), has been adopted at the annual general meeting held in Guangzhou, Guangdong Province, China today.

WALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 65,100 shares of the Company’s ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on June 25, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited (“Best Praise”), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.